Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics (NASDAQ: SLN) disclosed its Q1 2024 financials and recent advancements. The firm reported a cash position of £152.8 million ($192.8 million), up from £62.9 million ($77.8 million) a year prior. Collaboration revenue rose by £1.0 million to £12.4 million, largely due to a £9.2 million milestone payment from AstraZeneca. R&D expenses decreased by £3.4 million to £9.2 million, and G&A expenses dropped by £1.3 million to £5.2 million. This resulted in a net loss of £1.9 million, a significant improvement from the £10.2 million loss last year.
Key pipeline updates included positive 36-week data from the phase 2 ALPACAR-360 study of zerlasiran for cardiovascular disease, with primary endpoints met and no new safety concerns. Additionally, promising phase 1 data for divesiran in polycythemia vera (PV) patients were reported. Collaboratively, Silence achieved a $10 million milestone from AstraZeneca after initiating a phase 1 trial.
Silence Therapeutics plc, Nasdaq: SLN, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The Company focuses on precision engineered medicines to silence diseases, aiming to transform people's lives. The event will take place on May 20th, 2:30 p.m. ET, with a live webcast accessible on the Silence website and an archived replay available post-conference.
Silence Therapeutics plc announced the retirement of Alistair Gray, an independent member of the Board of Directors since 2015, effective May 1, 2024. Alistair Gray made significant contributions during his tenure, marking a period of growth and transformation for the company under the leadership of Iain Ross and Craig Tooman. The Company transitioned into a global player focusing on RNA interference, developed a pipeline of innovative product candidates, and secured big pharma partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.